Target intelligence / Profile preview

Gamma-crystallin C (CRYGC)

Target
CRYGC
Molecular classification
Other (Structural protein), Beta/gamma-crystallin family
01

Overview

Gamma-crystallin C is a member of the beta/gamma-crystallin family of highly stable, water-soluble structural proteins that constitute the major components of the vertebrate eye lens[1][3][7][8]. The primary function of gamma-crystallin C is to maintain lens transparency and its high refractive index, critical for vision[1][2][3][8]. These proteins are monomeric and highly symmetrical, forming dense, orderly arrangements within lens fiber cells, which lack nuclei and other organelles. Mutations in the CRYGC gene can disrupt protein stability and solubility, leading to various forms of cataract, especially in early-onset and familial cases. Gamma-crystallin C is not considered a druggable target in conventional therapeutic development, as its role is purely structural rather than catalytic or signaling[1][3][6][8].

Other names
Gamma-crystallin CCRYGCCRYG3Gamma-C-crystallinGamma-crystallin 2-1Gamma-crystallin 3CCLCTRCT2gamma-crystallin Cgamma-crystallin 2-1gamma-crystallin 3
02

Biological functions

Structural constituent of eye lensMaintenance of lens transparencyMaintenance of lens refractive index
03

Disease associations

Cataract (especially congenital forms such as Coppock-like cataract and zonular pulverulent cataract)Other (lens developmental disorders)
04

Safety considerations

Not applicable for drug targeting; mutations can cause cataracts, a disease concern, but not a drug or therapy safety issue
05

Biomarkers

Mutations in CRYGC as biomarkers for inherited cataracts

Beyond the preview

Go deeper on Gamma-crystallin C (CRYGC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-crystallin C (CRYGC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call